Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233381 | 0.88 | ALDH1A1 (0.56) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL2095973 | 0.85 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL2095975 | 0.85 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL12480670 | 0.85 | L3MBTL1 (0.61) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL4334835 | 0.84 | KMT2A (0.53) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL10310240 | 0.84 | ALDH1A1 (0.52) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL13170081 | 0.84 | L3MBTL1 (0.64) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL10180657 | 0.83 | LMNA (0.59) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL22369302 | 0.83 | LMNA (0.49) | ALDH1A1GAAMAPTHPGDALOX15 | |
| SCHEMBL2094767 | 0.83 | NPC1 (0.63) | ALDH1A1GAAMAPTHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638639-A | Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof | 中国药科大学 | 2025-03-18 | — | — | CN | claimed |
| EP-2611806-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Ascepion Pharmaceuticals, Inc. (CN) | 2013-07-10 | — | — | EP | claimed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | claimed |
| CN-119638639-A | Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof | 中国药科大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-114920703-B | Quinazoline derivative and preparation method and application thereof | 天津济坤医药科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4121415-A1 | INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2023-01-25 | — | — | EP | disclosed |
| CN-114920703-A | Quinazoline derivative and preparation method and application thereof | 天津济坤医药科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021185391-A1 | INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2021-09-23 | — | — | WO | disclosed |
| EP-3190969-B1 | METHOD FOR THE MANUFACTURING OF COATED IMPLANTS | CELL AND MOLECULAR TISSUE ENG LLC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200069409-A1 | Coated Surgical Mesh, and Corresponding Systems and Methods | Cell and Molecular Tissue Engineering, LLC | 2020-03-05 | — | — | US | disclosed |
| US-10405961-B2 | Coated surgical mesh, and corresponding systems and methods | Cell and Molecular Tissue Engineering, LLC (US) | 2019-09-10 | — | — | US | disclosed |
| US-20130274578-A1 | Artificial Tissue Systems and Uses Thereof | UNIVERSITY OF CONNECTICUT | 2013-10-17 | — | — | US | disclosed |
| CN-1993361-B | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP | 2010-05-26 | — | — | CN | disclosed |
| CN-101365454-A | Substituted 4-amino-pyrrolotriazine derivatives for the treatment of hyperproliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-1993361-A | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| US-20070077265-A1 | Article tissue systems and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-04-05 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1689321-A2 | ARTIFICIAL TISSUE SYSTEMS AND USES THEREOF | The University of Connecticut (US) | 2006-08-16 | — | — | EP | disclosed |
| CN-1787996-A | Nitrogen-containing heterocyclic derivative and drug containing the same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2006-06-14 | — | — | CN | disclosed |
| WO-2005046445-A2 | ARTIFICIAL TISSUE SYSTEMS AND USES THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | ALDH1A1 2069/4885GAA 266/4885MAPT 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.